<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01807234</url>
  </required_header>
  <id_info>
    <org_study_id>NA00075486</org_study_id>
    <nct_id>NCT01807234</nct_id>
  </id_info>
  <brief_title>Comparison of Ketorolac Nasal Spray to Sumatriptan Nasal Spray and Placebo for Acute Treatment of Migraine</brief_title>
  <acronym>KSPN</acronym>
  <official_title>Comparison of Ketorolac Nasal Spray to Sumatriptan Nasal Spray and Placebo for Acute Treatment of Migraine (The KSPN Migraine Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Luitpold Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators propose to test the efficacy of ketorolac nasal spray versus sumatriptan
      nasal spray versus placebo for acute abortive therapy of migraine head pain as well as for
      migraine associated symptoms including nausea and allodynia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants are randomized to Ketorolac NS 31.5 mg, Sumatriptan NS 20 mg or placebo to treat
      three moderate to severe migraine attacks and switched treatments with each attack so that
      they received each treatment only once.

      For each treated attack (moderate to severe migraine attack), participants utilized two study
      treatments (A and B). Study treatment A administered as one spray in each nostril, and study
      treatment B administered as one spray in one nostril.

      Randomized to Ketorolac, A=Ketorolac, B=Placebo Randomized to Sumatriptan, A=Placebo,
      B=Sumatriptan Randomized to Placebo, A=Placebo, B=Placebo
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>2- Hour Pain Relief</measure>
    <time_frame>2 hours</time_frame>
    <description>The primary outcome was 2-hour headache relief; headache relief was defined as headache pain from moderate or severe pain to none or mild pain. Pain was assessed using a 4-point scale (none, mild, moderate, and severe)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain Freedom</measure>
    <time_frame>2-hours</time_frame>
    <description>1) Pain Freedom: Pain Freedom at 2 hours is defined as being free of pain. Pain was assessed using a 4-point scale (none, mild, moderate, and severe).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absence of Photophobia</measure>
    <time_frame>2-hours</time_frame>
    <description>2) Defined as reduction of photophobia to none. Symptom was assessed using a 4-point scale (none, mild, moderate, and severe)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absence of Phonophobia</measure>
    <time_frame>2-hours</time_frame>
    <description>3) Defined as reduction of phonophobia to none. Symptom was assessed using a 4-point scale (none, mild, moderate, and severe)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absence of Nausea</measure>
    <time_frame>2-hours</time_frame>
    <description>4) Defined as reduction of nausea to none. Symptom was assessed using a 4-point scale (none, mild, moderate, and severe)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absence of Allodynia</measure>
    <time_frame>2-hours</time_frame>
    <description>5) Absence of allodynia The presence of allodynia was assessed based on a series of 8 questions inquiring as to the presence of allodynia. Participants answering 2 or more questions positively were considered to have allodynia.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Self-assessment of Disability: Percentage of Participants With Moderate or Severe Disability</measure>
    <time_frame>2-hours</time_frame>
    <description>Participants' self-assessment of disability was assessed using 4-point scales (none, mild, moderate, and severe). A binary outcome variable was created grouping none and mild vs moderate to severe. .</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sustained Pain Relief (SPR)</measure>
    <time_frame>24 and 48 hours</time_frame>
    <description>7) 24 and 48 hours sustained pain relief (SPR) Defined as the reduction of pain to none or mild from moderate or severe, on a 4-point scale (none, mild, moderate, and severe).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sustained Pain Freedom (SPF)</measure>
    <time_frame>24 and 48 hours</time_frame>
    <description>8) 24 and 48 hours sustained pain freedom (SPF); Defined as the reduction of pain to none. Pain was assessed using a 4-point scale (none, mild, moderate, and severe).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Pain Relief</measure>
    <time_frame>following each treated migraine attack</time_frame>
    <description>9) The time, in minutes, will be measured from the time study drug is taken to the time when significant pain relief is first observed and maintained through 2 hours with no rescue medication use at or prior to this point.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">72</enrollment>
  <condition>Migraines</condition>
  <arm_group>
    <arm_group_label>Ketorolac/Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ketorolac 31.5 mg single dose nasal spray and Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sumatriptan/Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sumatriptan 20 mg single dose nasal spray and placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ketorolac Placebo/Sumatriptan placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>single dose Ketorolac placebo, single dose Sumatriptan placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketorolac</intervention_name>
    <description>Single dose of Ketorolac (Sprix) nasal spray 31.5 mg, one spray in each nostril for an acute migraine attack.</description>
    <arm_group_label>Ketorolac/Placebo</arm_group_label>
    <other_name>Sprix</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sumatriptan</intervention_name>
    <description>Sumatriptan (Imitrex) 20 mg one single dose of nasal spray for an acute migraine attack.</description>
    <arm_group_label>Sumatriptan/Placebo</arm_group_label>
    <other_name>Imitrex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo one spray in each nostril and placebo one nasal spray.</description>
    <arm_group_label>Ketorolac/Placebo</arm_group_label>
    <arm_group_label>Sumatriptan/Placebo</arm_group_label>
    <arm_group_label>Ketorolac Placebo/Sumatriptan placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion/Exclusion Criteria

        At the Screening Visit, a subject must meet the following criteria to participate in this
        study:

        1.18-65 years of age 2.Fulfills International Classification of Headache Disorders
        (ICHD)-II Criteria of migraine as noted below in Table 1 3.History of migraines for at
        least one year 4.Migraine onset prior to the age of 50 years of age 5.Headache frequency
        (of any headaches, migraine or non-migraine) &lt; 9 days per month 6.At visit 2, participants
        must report two or more headache days during the 28-day run-in period on the headache
        diary. 7.At least 48 hours of freedom from headache between treated migraine attacks. 8.If
        currently using headache preventive medications, must be on a stable dose for at least 3
        months prior to enrollment and throughout the study period and be on no more than one
        prophylactic agent. 9.Able to complete all study procedures, including the questionnaire
        (assessing demographics, headache characteristics, headache comorbidities and medical
        history at the initial visit and headache characteristics) and the required headache
        calendars, and all study visits; 10.Able to understand, read and sign an informed consent
        (English).

        Exclusion Criteria:

          1. Any condition (history or presence of) which contraindicates the use of triptans or
             NSAIDs including:

               -  Known hypersensitivity or intolerance to triptans or NSAIDs

               -  Contraindications to triptan use (uncontrolled hypertension, ischemic heart
                  disease, prinz-metal angina, cardiac arrhythmias, multiple risk factors for
                  atherosclerotic vascular disease, primary vasculopathies, and basilar and
                  hemiplegic migraine)

               -  Cerebrovascular disease except for mild non-specific white matter disease

               -  Peripheral vascular disease or any other ischemic disease including myocardial
                  infarction

               -  Uncontrolled hypertension (systolic BP 160 mmHg or diastolic BP 95 mmHg or (both)

               -  Migraine aura fulfilling ICHD-II criteria for hemiplegic or basilar-type migraine

               -  Any history of chronic renal or hepatic impairment

               -  Use of an ergotamine-containing medication or monamine oxidase inhibitor

               -  Known or suspected pregnancy, negative pregnancy test

               -  Lactation

               -  Bleeding dsycrasias including gastritis, peptic ulcer disease,gastrointestinal
                  bleeding

          2. Physician diagnosis of any pain syndrome other than migraine

          3. Classification as treatment resistant by investigator

          4. Known drug or substance abuse

          5. Any opioid use in past 2 months

          6. Use of any medication, which could interfere with study assessments

          7. History of noncompliance with taking medication;

          8. Use of any experimental drug or device within 30 days prior to the Screening Visit
             (Visit 1);

          9. Any abnormal finding or condition deemed clinically significant by the investigator on
             history, screening, or physical exam that contraindicates the use of triptans or
             NSAIDs or that might interfere with the patient's safety, study participation, or
             which might confound the interpretation of the study results.

         10. Any history of chronic renal or hepatic disease already excluded above under number 1;
             plus see exclusion 9.

         11. History of chronic pulmonary disorder including nasal polyps (see 1) and asthma.

         12. History of upper respiratory infection or other respiratory tract condition that could
             interfere with the absorption of the nasal spray or with assessment of AEs including
             rhinitis medicamentosa (chronic daily use of topical decongestants).

         13. History of nasal surgery.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>The Johns Hopkins Bayview Headache Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 6, 2013</study_first_submitted>
  <study_first_submitted_qc>March 7, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 8, 2013</study_first_posted>
  <results_first_submitted>January 27, 2016</results_first_submitted>
  <results_first_submitted_qc>March 10, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">March 13, 2017</results_first_posted>
  <last_update_submitted>March 10, 2017</last_update_submitted>
  <last_update_submitted_qc>March 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Johns Hopkins University</investigator_affiliation>
    <investigator_full_name>Drs Barbara Peterlin</investigator_full_name>
    <investigator_title>Director, The Johns Hopkins Bayview Headache Research</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketorolac</mesh_term>
    <mesh_term>Ketorolac Tromethamine</mesh_term>
    <mesh_term>Sumatriptan</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Ketorolac Then Sumatriptan Then Placebo</title>
          <description>Participants were randomized for three attacks. For each treated attack, participants utilized two study treatments (A and B). Study treatment A administered as one spray in each nostril, and study treatment B administered as one spray in one nostril.
Randomized to Ketorolac, A=Ketorolac, B=Placebo Randomized to Sumatriptan, A=Placebo, B=Sumatriptan Randomized to Placebo, A=Placebo, B=Placebo
Attack 1: Ketorolac: Single dose of Ketorolac spray 31.5 kg, one spray in each nostril for acute migraine attack (Treatment A), placebo spray (Treatment B) in one nostril.
Attack 2: Sumatriptan: Placebo spray (treatment A) in one nostril, 20 mg single dose of Sumatriptan spray (Treatment B) into one nostril.
Attack 3: Placebo: Placebo spray (Treatment A) in each nostril, Placebo Spray (Treatment B) in each nostril.</description>
        </group>
        <group group_id="P2">
          <title>Kerorolac Then Placebo Then Sumatriptan</title>
          <description>Participants were randomized for three attacks. For each treated attack, participants utilized two study treatments (A and B). Study treatment A administered as one spray in each nostril, and study treatment B administered as one spray in one nostril.
Randomized to Ketorolac, A=Ketorolac, B=Placebo Randomized to Sumatriptan, A=Placebo, B=Sumatriptan Randomized to Placebo, A=Placebo, B=Placebo
Attack 1: Ketorolac: Single dose of Ketorolac spray 31.5 kg, one spray in each nostril for acute migraine attack (Treatment A), placebo spray (Treatment B) in one nostril.
Attack 2: Placebo: Placebo spray (Treatment A) in each nostril, Placebo Spray (Treatment B) in each nostril.
Attack 3: Sumatriptan: Placebo spray (treatment A) in one nostril, 20 mg single dose of Sumatriptan spray (Treatment B) into one nostril.</description>
        </group>
        <group group_id="P3">
          <title>Sumatriptan Then Ketorolac Then Placebo</title>
          <description>Participants were randomized for three attacks. For each treated attack, participants utilized two study treatments (A and B). Study treatment A administered as one spray in each nostril, and study treatment B administered as one spray in one nostril.
Randomized to Ketorolac, A=Ketorolac, B=Placebo Randomized to Sumatriptan, A=Placebo, B=Sumatriptan Randomized to Placebo, A=Placebo, B=Placebo
Attack 1: Sumatriptan: Placebo spray (treatment A) in one nostril, 20 mg single dose of Sumatriptan spray (Treatment B) into one nostril.
Attack 2: Ketorolac: Single dose of Ketorolac spray 31.5 kg, one spray in each nostril for acute migraine attack (Treatment A), placebo spray (Treatment B) in one nostril.
Attack 3: Placebo: Placebo spray (Treatment A) in each nostril, Placebo Spray (Treatment B) in each nostril.</description>
        </group>
        <group group_id="P4">
          <title>Sumatriptan Then Placebo Then Ketorolac</title>
          <description>Participants were randomized for three attacks. For each treated attack, participants utilized two study treatments (A and B). Study treatment A administered as one spray in each nostril, and study treatment B administered as one spray in one nostril.
Randomized to Ketorolac, A=Ketorolac, B=Placebo Randomized to Sumatriptan, A=Placebo, B=Sumatriptan Randomized to Placebo, A=Placebo, B=Placebo
Attack 1: Sumatriptan: Placebo spray (treatment A) in one nostril, 20 mg single dose of Sumatriptan spray (Treatment B) into one nostril.
Attack 2: Placebo: Placebo spray (Treatment A) in each nostril, Placebo Spray (Treatment B) in each nostril.
Attack 3: Ketorolac: Single dose of Ketorolac spray 31.5 kg, one spray in each nostril for acute migraine attack (Treatment A), placebo spray (Treatment B) in one nostril.</description>
        </group>
        <group group_id="P5">
          <title>Placebo Then Ketorolac Then Sumatriptan</title>
          <description>Participants were randomized for three attacks. For each treated attack, participants utilized two study treatments (A and B). Study treatment A administered as one spray in each nostril, and study treatment B administered as one spray in one nostril.
Randomized to Ketorolac, A=Ketorolac, B=Placebo Randomized to Sumatriptan, A=Placebo, B=Sumatriptan Randomized to Placebo, A=Placebo, B=Placebo
Attack 1: Placebo: Placebo spray (Treatment A) in each nostril, Placebo Spray (Treatment B) in each nostril.
Attack 2: Ketorolac: Single dose of Ketorolac spray 31.5 kg, one spray in each nostril for acute migraine attack (Treatment A), placebo spray (Treatment B) in one nostril.
Attack 3: Sumatriptan: Placebo spray (treatment A) in one nostril, 20 mg single dose of Sumatriptan spray (Treatment B) into one nostril.</description>
        </group>
        <group group_id="P6">
          <title>Placebo Then Sumatriptan Then Ketorolac</title>
          <description>Participants were randomized for three attacks. For each treated attack, participants utilized two study treatments (A and B). Study treatment A administered as one spray in each nostril, and study treatment B administered as one spray in one nostril.
Randomized to Ketorolac, A=Ketorolac, B=Placebo Randomized to Sumatriptan, A=Placebo, B=Sumatriptan Randomized to Placebo, A=Placebo, B=Placebo
Attack 1: Placebo: Placebo spray (Treatment A) in each nostril, Placebo Spray (Treatment B) in each nostril.
Attack 2: Sumatriptan: Placebo spray (treatment A) in one nostril, 20 mg single dose of Sumatriptan spray (Treatment B) into one nostril.
Attack 3: Ketorolac: Single dose of Ketorolac spray 31.5 kg, one spray in each nostril for acute migraine attack (Treatment A), placebo spray (Treatment B) in one nostril.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="12"/>
                <participants group_id="P5" count="12"/>
                <participants group_id="P6" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Randomized, But Did Not Take Drug</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed Only 1 Attack</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="10"/>
                <participants group_id="P5" count="8"/>
                <participants group_id="P6" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Of the 72 randomized participants, 54 (75%) treated at least one attack and 49 (68%) completed all three treatments, for a total of 152 treated migraine attacks.</population>
      <group_list>
        <group group_id="B1">
          <title>Ketorolac Then Sumatriptan Then Placebo</title>
          <description>Participants were randomized for three attacks. For each treated attack, participants utilized two study treatments (A and B). Study treatment A administered as one spray in each nostril, and study treatment B administered as one spray in one nostril.
Randomized to Ketorolac, A=Ketorolac, B=Placebo Randomized to Sumatriptan, A=Placebo, B=Sumatriptan Randomized to Placebo, A=Placebo, B=Placebo
Attack 1: Ketorolac: Single dose of Ketorolac spray 31.5 kg, one spray in each nostril for acute migraine attack (Treatment A), placebo spray (Treatment B) in one nostril.
Attack 2: Sumatriptan: Placebo spray (treatment A) in one nostril, 20 mg single dose of Sumatriptan spray (Treatment B) into one nostril.
Attack 3: Placebo: Placebo spray (Treatment A) in each nostril, Placebo Spray (Treatment B) in each nostril.</description>
        </group>
        <group group_id="B2">
          <title>Ketorolac Then Placebo Then Sumatriptan</title>
          <description>Participants were randomized for three attacks. For each treated attack, participants utilized two study treatments (A and B). Study treatment A administered as one spray in each nostril, and study treatment B administered as one spray in one nostril.
Randomized to Ketorolac, A=Ketorolac, B=Placebo Randomized to Sumatriptan, A=Placebo, B=Sumatriptan Randomized to Placebo, A=Placebo, B=Placebo
Attack 1: Ketorolac: Single dose of Ketorolac spray 31.5 kg, one spray in each nostril for acute migraine attack (Treatment A), placebo spray (Treatment B) in one nostril.
Attack 2: Placebo: Placebo spray (Treatment A) in each nostril, Placebo Spray (Treatment B) in each nostril.
Attack 3: Sumatriptan: Placebo spray (treatment A) in one nostril, 20 mg single dose of Sumatriptan spray (Treatment B) into one nostril.</description>
        </group>
        <group group_id="B3">
          <title>Sumatriptan Then Ketorolac Then Placebo</title>
          <description>Participants were randomized for three attacks. For each treated attack, participants utilized two study treatments (A and B). Study treatment A administered as one spray in each nostril, and study treatment B administered as one spray in one nostril.
Randomized to Ketorolac, A=Ketorolac, B=Placebo Randomized to Sumatriptan, A=Placebo, B=Sumatriptan Randomized to Placebo, A=Placebo, B=Placebo
Attack 1: Sumatriptan: Placebo spray (treatment A) in one nostril, 20 mg single dose of Sumatriptan spray (Treatment B) into one nostril.
Attack 2: Ketorolac: Single dose of Ketorolac spray 31.5 kg, one spray in each nostril for acute migraine attack (Treatment A), placebo spray (Treatment B) in one nostril.
Attack 3: Placebo: Placebo spray (Treatment A) in each nostril, Placebo Spray (Treatment B) in each nostril.</description>
        </group>
        <group group_id="B4">
          <title>Sumatriptan Then Placebo Then Ketorolac</title>
          <description>Participants were randomized for three attacks. For each treated attack, participants utilized two study treatments (A and B). Study treatment A administered as one spray in each nostril, and study treatment B administered as one spray in one nostril.
Randomized to Ketorolac, A=Ketorolac, B=Placebo Randomized to Sumatriptan, A=Placebo, B=Sumatriptan Randomized to Placebo, A=Placebo, B=Placebo
Attack 1: Sumatriptan: Placebo spray (treatment A) in one nostril, 20 mg single dose of Sumatriptan spray (Treatment B) into one nostril.
Attack 2: Placebo: Placebo spray (Treatment A) in each nostril, Placebo Spray (Treatment B) in each nostril.
Attack 3: Ketorolac: Single dose of Ketorolac spray 31.5 kg, one spray in each nostril for acute migraine attack (Treatment A), placebo spray (Treatment B) in one nostril.</description>
        </group>
        <group group_id="B5">
          <title>Placebo Then Ketorolac Then Sumatriptan</title>
          <description>Participants were randomized for three attacks. For each treated attack, participants utilized two study treatments (A and B). Study treatment A administered as one spray in each nostril, and study treatment B administered as one spray in one nostril.
Randomized to Ketorolac, A=Ketorolac, B=Placebo Randomized to Sumatriptan, A=Placebo, B=Sumatriptan Randomized to Placebo, A=Placebo, B=Placebo
Attack 1: Placebo: Placebo spray (Treatment A) in each nostril, Placebo Spray (Treatment B) in each nostril.
Attack 2: Ketorolac: Single dose of Ketorolac spray 31.5 kg, one spray in each nostril for acute migraine attack (Treatment A), placebo spray (Treatment B) in one nostril.
Attack 3: Sumatriptan: Placebo spray (treatment A) in one nostril, 20 mg single dose of Sumatriptan spray (Treatment B) into one nostril.</description>
        </group>
        <group group_id="B6">
          <title>Placebo Then Sumatriptan Then Ketorolac</title>
          <description>Participants were randomized for three attacks. For each treated attack, participants utilized two study treatments (A and B). Study treatment A administered as one spray in each nostril, and study treatment B administered as one spray in one nostril.
Randomized to Ketorolac, A=Ketorolac, B=Placebo Randomized to Sumatriptan, A=Placebo, B=Sumatriptan Randomized to Placebo, A=Placebo, B=Placebo
Attack 1: Placebo: Placebo spray (Treatment A) in each nostril, Placebo Spray (Treatment B) in each nostril.
Attack 2: Sumatriptan: Placebo spray (treatment A) in one nostril, 20 mg single dose of Sumatriptan spray (Treatment B) into one nostril.
Attack 3: Ketorolac: Single dose of Ketorolac spray 31.5 kg, one spray in each nostril for acute migraine attack (Treatment A), placebo spray (Treatment B) in one nostril.</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
            <count group_id="B2" value="12"/>
            <count group_id="B3" value="12"/>
            <count group_id="B4" value="12"/>
            <count group_id="B5" value="12"/>
            <count group_id="B6" value="12"/>
            <count group_id="B7" value="72"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="12"/>
                    <measurement group_id="B5" value="12"/>
                    <measurement group_id="B6" value="12"/>
                    <measurement group_id="B7" value="72"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <description>Average age of participants</description>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36.3" spread="9.8"/>
                    <measurement group_id="B2" value="36.3" spread="9.8"/>
                    <measurement group_id="B3" value="36.3" spread="9.8"/>
                    <measurement group_id="B4" value="36.3" spread="9.8"/>
                    <measurement group_id="B5" value="36.3" spread="9.8"/>
                    <measurement group_id="B6" value="36.3" spread="9.8"/>
                    <measurement group_id="B7" value="36.3" spread="9.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="12"/>
                    <measurement group_id="B5" value="12"/>
                    <measurement group_id="B6" value="11"/>
                    <measurement group_id="B7" value="70"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="12"/>
                    <measurement group_id="B5" value="12"/>
                    <measurement group_id="B6" value="12"/>
                    <measurement group_id="B7" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>2- Hour Pain Relief</title>
        <description>The primary outcome was 2-hour headache relief; headache relief was defined as headache pain from moderate or severe pain to none or mild pain. Pain was assessed using a 4-point scale (none, mild, moderate, and severe)</description>
        <time_frame>2 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ketorolac/ Placebo</title>
            <description>Ketorolac 31.5 mg single dose nasal spray and Placebo
Ketorolac: Single dose of Ketorolac nasal spray 31.5 mg, one spray in each nostril for an acute migraine attack.
Placebo: Ketorolac placebo one spray in each nostril and Sumatriptan placebo one nasal spray.</description>
          </group>
          <group group_id="O2">
            <title>Sumatriptan/ Placebo</title>
            <description>Sumatriptan 20 mg single dose nasal spray and placebo
Sumatriptan: Sumatriptan 20 mg one single dose of nasal spray for an acute migraine attack.
Placebo: SPRIX placebo one spray in each nostril and Sumatriptan placebo one nasal spray.</description>
          </group>
          <group group_id="O3">
            <title>Ketorolac Placebo/ Sumatriptan Placebo</title>
            <description>Single dose Ketorolac placebo, single dose Sumatriptan placebo
Placebo: Ketorolac placebo one spray in each nostril and Sumatriptan placebo one nasal spray.</description>
          </group>
        </group_list>
        <measure>
          <title>2- Hour Pain Relief</title>
          <description>The primary outcome was 2-hour headache relief; headache relief was defined as headache pain from moderate or severe pain to none or mild pain. Pain was assessed using a 4-point scale (none, mild, moderate, and severe)</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.5" lower_limit="59.9" upper_limit="85.2"/>
                    <measurement group_id="O2" value="69.4" lower_limit="56.0" upper_limit="82.8"/>
                    <measurement group_id="O3" value="38.8" lower_limit="24.6" upper_limit="52.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain Freedom</title>
        <description>1) Pain Freedom: Pain Freedom at 2 hours is defined as being free of pain. Pain was assessed using a 4-point scale (none, mild, moderate, and severe).</description>
        <time_frame>2-hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ketorolac/ Placebo</title>
            <description>Ketorolac 31.5 mg single dose nasal spray and Placebo
Ketorolac: Single dose of Ketorolac nasal spray 31.5 mg, one spray in each nostril for an acute migraine attack.
Placebo: Ketorolac placebo one spray in each nostril and Sumatriptan placebo one nasal spray.</description>
          </group>
          <group group_id="O2">
            <title>Sumatriptan/Placebo</title>
            <description>Sumatriptan 20 mg single dose nasal spray and placebo
Sumatriptan: Sumatriptan 20 mg one single dose of nasal spray for an acute migraine attack.
Placebo: Ketorolac placebo one spray in each nostril and Sumatriptan placebo one nasal spray.</description>
          </group>
          <group group_id="O3">
            <title>Ketorolac Placebo/ Sumatriptan Placebo</title>
            <description>Single dose Ketorolac placebo, single dose Sumatriptan placebo
Placebo: Ketorolac placebo one spray in each nostril and Sumatriptan placebo one nasal spray.</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Freedom</title>
          <description>1) Pain Freedom: Pain Freedom at 2 hours is defined as being free of pain. Pain was assessed using a 4-point scale (none, mild, moderate, and severe).</description>
          <units>percentage of patients</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.1" lower_limit="29.1" upper_limit="57.2"/>
                    <measurement group_id="O2" value="36.7" lower_limit="22.7" upper_limit="50.7"/>
                    <measurement group_id="O3" value="18.4" lower_limit="7.1" upper_limit="29.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absence of Photophobia</title>
        <description>2) Defined as reduction of photophobia to none. Symptom was assessed using a 4-point scale (none, mild, moderate, and severe)</description>
        <time_frame>2-hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ketorolac/ Placebo</title>
            <description>Ketorolac 31.5 mg single dose nasal spray and Placebo
Ketorolac: Single dose of Ketorolac nasal spray 31.5 mg, one spray in each nostril for an acute migraine attack.
Placebo: Ketorolac placebo one spray in each nostril and Sumatriptan placebo one nasal spray.</description>
          </group>
          <group group_id="O2">
            <title>Sumatriptan/ Placebo</title>
            <description>Sumatriptan 20 mg single dose nasal spray and placebo
Sumatriptan: Sumatriptan 20 mg one single dose of nasal spray for an acute migraine attack.
Placebo: Ketorolac placebo one spray in each nostril and Sumatriptan placebo one nasal spray.</description>
          </group>
          <group group_id="O3">
            <title>Ketorolac Placebo/ Sumatriptan Placebo</title>
            <description>Single dose Ketorolac placebo, single dose Sumatriptan placebo
Placebo: Ketorolac placebo one spray in each nostril and Sumatriptan placebo one nasal spray.</description>
          </group>
        </group_list>
        <measure>
          <title>Absence of Photophobia</title>
          <description>2) Defined as reduction of photophobia to none. Symptom was assessed using a 4-point scale (none, mild, moderate, and severe)</description>
          <units>percentage of patients</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.4" lower_limit="56.1" upper_limit="74.7"/>
                    <measurement group_id="O2" value="64.0" lower_limit="54.4" upper_limit="73.6"/>
                    <measurement group_id="O3" value="46.0" lower_limit="36.1" upper_limit="55.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absence of Phonophobia</title>
        <description>3) Defined as reduction of phonophobia to none. Symptom was assessed using a 4-point scale (none, mild, moderate, and severe)</description>
        <time_frame>2-hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ketorolac/ Placebo</title>
            <description>Ketorolac 31.5 mg single dose nasal spray and Placebo
Ketorolac: Single dose of Ketorolac nasal spray 31.5 mg, one spray in each nostril for an acute migraine attack.
Placebo: Ketorolac placebo one spray in each nostril and Sumatriptan placebo one nasal spray.</description>
          </group>
          <group group_id="O2">
            <title>Sumatriptan/Placebo</title>
            <description>Sumatriptan 20 mg single dose nasal spray and placebo
Sumatriptan: Sumatriptan 20 mg one single dose of nasal spray for an acute migraine attack.
Placebo: Ketorolac placebo one spray in each nostril and Sumatriptan placebo one nasal spray.</description>
          </group>
          <group group_id="O3">
            <title>Ketorolac Placebo/ Sumatriptan Placebo</title>
            <description>Single dose Ketorolac placebo, single dose Sumatriptan placebo
Placebo: Ketorolac placebo one spray in each nostril and Sumatriptan placebo one nasal spray.</description>
          </group>
        </group_list>
        <measure>
          <title>Absence of Phonophobia</title>
          <description>3) Defined as reduction of phonophobia to none. Symptom was assessed using a 4-point scale (none, mild, moderate, and severe)</description>
          <units>percentage of patients</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.0" lower_limit="66.5" upper_limit="83.4"/>
                    <measurement group_id="O2" value="66.0" lower_limit="56.5" upper_limit="75.4"/>
                    <measurement group_id="O3" value="56.0" lower_limit="46.1" upper_limit="65.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absence of Nausea</title>
        <description>4) Defined as reduction of nausea to none. Symptom was assessed using a 4-point scale (none, mild, moderate, and severe)</description>
        <time_frame>2-hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ketorolac/ Placebo</title>
            <description>Ketorolac 31.5 mg single dose nasal spray and Placebo
Ketorolac: Single dose of Ketorolac nasal spray 31.5 mg, one spray in each nostril for an acute migraine attack.
Placebo: Ketorolac placebo one spray in each nostril and Sumatriptan placebo one nasal spray.</description>
          </group>
          <group group_id="O2">
            <title>Sumatriptan/ Placebo</title>
            <description>Sumatriptan 20 mg single dose nasal spray and placebo
Sumatriptan: Sumatriptan 20 mg one single dose of nasal spray for an acute migraine attack.
Placebo: Ketorolac placebo one spray in each nostril and Sumatriptan placebo one nasal spray.</description>
          </group>
          <group group_id="O3">
            <title>Ketorolac Placebo/ Sumatriptan Placebo</title>
            <description>Single dose Ketorolac placebo, single dose Sumatriptan placebo
Placebo: Ketorolac placebo one spray in each nostril and Sumatriptan placebo one nasal spray.</description>
          </group>
        </group_list>
        <measure>
          <title>Absence of Nausea</title>
          <description>4) Defined as reduction of nausea to none. Symptom was assessed using a 4-point scale (none, mild, moderate, and severe)</description>
          <units>percentage of patients</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.7" lower_limit="75.3" upper_limit="90.0"/>
                    <measurement group_id="O2" value="74.0" lower_limit="65.2" upper_limit="82.7"/>
                    <measurement group_id="O3" value="66.0" lower_limit="56.5" upper_limit="75.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absence of Allodynia</title>
        <description>5) Absence of allodynia The presence of allodynia was assessed based on a series of 8 questions inquiring as to the presence of allodynia. Participants answering 2 or more questions positively were considered to have allodynia.</description>
        <time_frame>2-hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ketorolac/ Placebo</title>
            <description>Ketorolac 31.5 mg single dose nasal spray and Placebo
Ketorolac: Single dose of Ketorolac nasal spray 31.5 mg, one spray in each nostril for an acute migraine attack.
Placebo: Ketorolac placebo one spray in each nostril and Sumatriptan placebo one nasal spray.</description>
          </group>
          <group group_id="O2">
            <title>Sumatriptan/ Placebo</title>
            <description>Sumatriptan 20 mg single dose nasal spray and placebo
Sumatriptan: Sumatriptan 20 mg one single dose of nasal spray for an acute migraine attack.
Placebo: Ketorolac placebo one spray in each nostril and Sumatriptan placebo one nasal spray.</description>
          </group>
          <group group_id="O3">
            <title>Ketorolac Placebo/ Sumatriptan Placebo</title>
            <description>Single dose Ketorolac placebo, single dose Sumatriptan placebo
Placebo: Ketorolac placebo one spray in each nostril and Sumatriptan placebo one nasal spray.</description>
          </group>
        </group_list>
        <measure>
          <title>Absence of Allodynia</title>
          <description>5) Absence of allodynia The presence of allodynia was assessed based on a series of 8 questions inquiring as to the presence of allodynia. Participants answering 2 or more questions positively were considered to have allodynia.</description>
          <units>percentage of patients</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.5" lower_limit="57.6" upper_limit="83.5"/>
                    <measurement group_id="O2" value="75.5" lower_limit="63.0" upper_limit="87.9"/>
                    <measurement group_id="O3" value="69.0" lower_limit="57.6" upper_limit="83.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Self-assessment of Disability: Percentage of Participants With Moderate or Severe Disability</title>
        <description>Participants self-assessment of disability was assessed using 4-point scales (none, mild, moderate, and severe). A binary outcome variable was created grouping none and mild vs moderate to severe. .</description>
        <time_frame>2-hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ketorolac/ Placebo</title>
            <description>Ketorolac 31.5 mg single dose nasal spray and Placebo
Ketorolac: Single dose of Ketorolac nasal spray 31.5 mg, one spray in each nostril for an acute migraine attack.
Placebo: Ketorolac placebo one spray in each nostril and Sumatriptan placebo one nasal spray.</description>
          </group>
          <group group_id="O2">
            <title>Sumatriptan/ Placebo</title>
            <description>Sumatriptan 20 mg single dose nasal spray and placebo
Sumatriptan: Sumatriptan 20 mg one single dose of nasal spray for an acute migraine attack.
Placebo: Ketorolac placebo one spray in each nostril and Sumatriptan placebo one nasal spray.</description>
          </group>
          <group group_id="O3">
            <title>Ketorolac Placebo/ Sumatriptan Placebo</title>
            <description>Single dose Ketorolac placebo, single dose Sumatriptan placebo
Placebo: Ketorolac placebo one spray in each nostril and Sumatriptan placebo one nasal spray.</description>
          </group>
        </group_list>
        <measure>
          <title>Self-assessment of Disability: Percentage of Participants With Moderate or Severe Disability</title>
          <description>Participants self-assessment of disability was assessed using 4-point scales (none, mild, moderate, and severe). A binary outcome variable was created grouping none and mild vs moderate to severe. .</description>
          <units>percentage of patients</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9" lower_limit="0.2" upper_limit="13.1"/>
                    <measurement group_id="O2" value="8.1" lower_limit="3.0" upper_limit="20.1"/>
                    <measurement group_id="O3" value="10.2" lower_limit="4.2" upper_limit="22.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sustained Pain Relief (SPR)</title>
        <description>7) 24 and 48 hours sustained pain relief (SPR) Defined as the reduction of pain to none or mild from moderate or severe, on a 4-point scale (none, mild, moderate, and severe).</description>
        <time_frame>24 and 48 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ketorolac/ Placebo</title>
            <description>Ketorolac 31.5 mg single dose nasal spray and Placebo
Ketorolac: Single dose of Ketorolac nasal spray 31.5 mg, one spray in each nostril for an acute migraine attack.
Placebo: Ketorolac placebo one spray in each nostril and Sumatriptan placebo one nasal spray.</description>
          </group>
          <group group_id="O2">
            <title>Sumatriptan/ Placebo</title>
            <description>Sumatriptan 20 mg single dose nasal spray and placebo
Sumatriptan: Sumatriptan 20 mg one single dose of nasal spray for an acute migraine attack.
Placebo: Ketorolac placebo one spray in each nostril and Sumatriptan placebo one nasal spray.</description>
          </group>
          <group group_id="O3">
            <title>Ketorolac Placebo/ Sumatriptan Placebo</title>
            <description>Single dose Ketorolac placebo, single dose Sumatriptan placebo
Placebo: Ketorolac placebo one spray in each nostril and Sumatriptan placebo one nasal spray.</description>
          </group>
        </group_list>
        <measure>
          <title>Sustained Pain Relief (SPR)</title>
          <description>7) 24 and 48 hours sustained pain relief (SPR) Defined as the reduction of pain to none or mild from moderate or severe, on a 4-point scale (none, mild, moderate, and severe).</description>
          <units>percentage of patients</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>24 hour sustained pain relief</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.0" lower_limit="34.8" upper_limit="63.2"/>
                    <measurement group_id="O2" value="40.8" lower_limit="26.5" upper_limit="55.1"/>
                    <measurement group_id="O3" value="20.4" lower_limit="8.7" upper_limit="32.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>48 hour sustained pain relief</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.0" lower_limit="34.8" upper_limit="63.2"/>
                    <measurement group_id="O2" value="30.6" lower_limit="17.2" upper_limit="43.9"/>
                    <measurement group_id="O3" value="20.4" lower_limit="8.7" upper_limit="32.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sustained Pain Freedom (SPF)</title>
        <description>8) 24 and 48 hours sustained pain freedom (SPF); Defined as the reduction of pain to none. Pain was assessed using a 4-point scale (none, mild, moderate, and severe).</description>
        <time_frame>24 and 48 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ketorolac/ Placebo</title>
            <description>Ketorolac 31.5 mg single dose nasal spray and Placebo
Ketorolac: Single dose of Ketorolac nasal spray 31.5 mg, one spray in each nostril for an acute migraine attack.
Placebo: Ketorolac placebo one spray in each nostril and Sumatriptan placebo one nasal spray.</description>
          </group>
          <group group_id="O2">
            <title>Sumatriptan/ Placebo</title>
            <description>Sumatriptan 20 mg single dose nasal spray and placebo
Sumatriptan: Sumatriptan 20 mg one single dose of nasal spray for an acute migraine attack.
Placebo: Ketorolac placebo one spray in each nostril and Sumatriptan placebo one nasal spray.</description>
          </group>
          <group group_id="O3">
            <title>Ketorolac Placebo/ Sumatriptan Placebo</title>
            <description>Single dose Ketorolac placebo, single dose Sumatriptan placebo
Placebo: Ketorolac placebo one spray in each nostril and Sumatriptan placebo one nasal spray.</description>
          </group>
        </group_list>
        <measure>
          <title>Sustained Pain Freedom (SPF)</title>
          <description>8) 24 and 48 hours sustained pain freedom (SPF); Defined as the reduction of pain to none. Pain was assessed using a 4-point scale (none, mild, moderate, and severe).</description>
          <units>percentage of patients</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>24 hour sustained pain freedom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.3" lower_limit="21.7" upper_limit="48.9"/>
                    <measurement group_id="O2" value="22.4" lower_limit="10.3" upper_limit="34.5"/>
                    <measurement group_id="O3" value="12.2" lower_limit="2.7" upper_limit="21.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>48 hour sustained pain freedom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.3" lower_limit="19.9" upper_limit="46.7"/>
                    <measurement group_id="O2" value="18.4" lower_limit="7.1" upper_limit="29.6"/>
                    <measurement group_id="O3" value="12.2" lower_limit="2.7" upper_limit="21.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Pain Relief</title>
        <description>9) The time, in minutes, will be measured from the time study drug is taken to the time when significant pain relief is first observed and maintained through 2 hours with no rescue medication use at or prior to this point.</description>
        <time_frame>following each treated migraine attack</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ketorolac/ Placebo</title>
            <description>Ketorolac 31.5 mg single dose nasal spray and Placebo
Ketorolac: Single dose of Ketorolac nasal spray 31.5 mg, one spray in each nostril for an acute migraine attack.
Placebo: Ketorolac placebo one spray in each nostril and Sumatriptan placebo one nasal spray.</description>
          </group>
          <group group_id="O2">
            <title>Sumatriptan/ Placebo</title>
            <description>Sumatriptan 20 mg single dose nasal spray and placebo
Sumatriptan: Sumatriptan 20 mg one single dose of nasal spray for an acute migraine attack.
Placebo: Ketorolac placebo one spray in each nostril and Sumatriptan placebo one nasal spray.</description>
          </group>
          <group group_id="O3">
            <title>Ketorolac Placebo/ Sumatriptan Placebo</title>
            <description>Single dose Ketorolac placebo, single dose Sumatriptan placebo
Placebo: Ketorolac placebo one spray in each nostril and Sumatriptan placebo one nasal spray.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Pain Relief</title>
          <description>9) The time, in minutes, will be measured from the time study drug is taken to the time when significant pain relief is first observed and maintained through 2 hours with no rescue medication use at or prior to this point.</description>
          <units>percentage of patients</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>10 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.7" lower_limit="5.3" upper_limit="26.0"/>
                    <measurement group_id="O2" value="14.3" lower_limit="4.1" upper_limit="24.4"/>
                    <measurement group_id="O3" value="12.2" lower_limit="2.7" upper_limit="21.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>15 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.3" lower_limit="21.7" upper_limit="48.8"/>
                    <measurement group_id="O2" value="36.0" lower_limit="22.2" upper_limit="49.7"/>
                    <measurement group_id="O3" value="14.3" lower_limit="4.1" upper_limit="24.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.1" lower_limit="29.1" upper_limit="57.2"/>
                    <measurement group_id="O2" value="44.9" lower_limit="30.4" upper_limit="59.3"/>
                    <measurement group_id="O3" value="22.4" lower_limit="10.3" upper_limit="34.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.9" lower_limit="40.7" upper_limit="69.0"/>
                    <measurement group_id="O2" value="53.1" lower_limit="38.6" upper_limit="67.5"/>
                    <measurement group_id="O3" value="26.5" lower_limit="13.7" upper_limit="39.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.8" lower_limit="44.8" upper_limit="72.8"/>
                    <measurement group_id="O2" value="57.1" lower_limit="42.8" upper_limit="71.5"/>
                    <measurement group_id="O3" value="32.6" lower_limit="19.0" upper_limit="46.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data was collected at the 10 minute, 15 minute, 20 minute, 30 minute, 60 minute, 2 hour, 24 hour and 72 hour mark.</time_frame>
      <desc>At each of the time intervals listed above, participants were instructed to document any adverse effects from drug that occured.</desc>
      <group_list>
        <group group_id="E1">
          <title>Sprix/Placebo</title>
          <description>Sprix 31.5 mg single dose nasal spray and Placebo
SPRIX: Single dose of Sprix nasal spray 31.5 mg, one spray in each nostril for an acute migraine attack.
Placebo: SPRIX placebo one spray in each nostril and Sumatriptan placebo one nasal spray.
The most common adverse events reported by participants treated with ketorolac NS were burning of nose, (mild in 25.5%, moderate in 19.6% and severe in 3.9%), unusual taste (mild in 2%, moderate in 5.9%, severe 2%), nasal discomfort (8%), burning of throat (6%), fatigue (4%), dizziness (4%), nausea (2%), rash (2%).</description>
        </group>
        <group group_id="E2">
          <title>Sumatriptan/Placebo</title>
          <description>Sumatriptan 20 mg single dose nasal spray and placebo
Sumatriptan: Sumatriptan 20 mg one single dose of nasal spray for an acute migraine attack.
Placebo: SPRIX placebo one spray in each nostril and Sumatriptan placebo one nasal spray.
For those treated with sumatriptan NS the most common adverse events were unusual taste (mild in 24.5%, moderate in 12.2%, severe 4.1%), burning of the nose (mild in 6.1%, moderate in 2%), nausea (8%), burning of the throat (6%), nasal discomfort (6%), dizziness (4%), fatigue (4%) and rash (2%).</description>
        </group>
        <group group_id="E3">
          <title>SRIX Placebo/Sumatriptan Placebo</title>
          <description>single dose SPRIX placebo, single dose Sumatriptan placebo
Placebo: SPRIX placebo one spray in each nostril and Sumatriptan placebo one nasal spray.
The most common adverse event for placebo were unusual taste (mild in 4%, moderate in 2%), nausea (4%), rash (4%), fatigue (4%), burning of the nose (2%), dizziness (2%).</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedWatch</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>fatigue</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>mild unusual taste</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>moderate unusual taste</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>severe unusual taste</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>dizziness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>mild burning of nose</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>moderate burning of nose</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>severe burning of nose</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>nasal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>burning of throat</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Small study size (n=54)</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. B. Lee Peterlin</name_or_title>
      <organization>Johns Hopkins University School of Medicine</organization>
      <phone>410-550-9550</phone>
      <email>hnitchi1@jhmi.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

